PPT-Figure 2 Figure 2. Determination of prevalence of tuberculosis (TB) and drug

Author : megan | Published Date : 2024-02-09

Shah N Richardson J Moodley P Moodley S Babaria P Ramtahal M et al Increasing Drug Resistance in Extensively DrugResistant Tuberculosis South Africa Emerg Infect

Presentation Embed Code

Download Presentation

Download Presentation The PPT/PDF document "Figure 2 Figure 2. Determinatio..." is the property of its rightful owner. Permission is granted to download and print the materials on this website for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.

Figure 2 Figure 2. Determination of prevalence of tuberculosis (TB) and drug: Transcript

Shah N Richardson J Moodley P Moodley S Babaria P Ramtahal M et al Increasing Drug Resistance in Extensively DrugResistant Tuberculosis South Africa Emerg Infect Dis 2011173510513 httpsdoiorg103201eid1703101363. Murase Y, Maeda S, Yamada H, Ohkado A, Chikamatsu K, Mizuno K, et al. Clonal Expansion of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis, Japan. Emerg Infect Dis. 2010;16(6):948-954. https://doi.org/10.3201/eid1606.091844. Bansal V, Metzner KJ, Niederöst B, Leemann C, Böni J, Günthard HF, et al. Minority K65R Variants and Early Failure of Antiretroviral Therapy in HIV-1–infected Eritrean Immigrant. Emerg Infect Dis. 2011;17(10):1966-1968. https://doi.org/10.3201/eid1710.110592. Cosivi O, Grange J, Daborn C, Raviglione M, Fujikura T, Cousins D, et al. Zoonotic Tuberculosis due to Mycobacterium bovis in Developing Countries. Emerg Infect Dis. 1998;4(1):59-70. https://doi.org/10.3201/eid0401.980108. Rattan A, Kalia A, Ahmad N. Multidrug-Resistant Mycobacterium tuberculosis: Molecular Perspectives. Emerg Infect Dis. 1998;4(2):195-209. https://doi.org/10.3201/eid0402.980207. Sola C, Devallois A, Horgen L, Maïsetti J, Filliol I, Legrand E, et al. Tuberculosis in the Caribbean: Using Spacer Oligonucleotide Typing to Understand Strain Origin and Transmission. Emerg Infect Dis. 1999;5(3):404-411. https://doi.org/10.3201/eid0503.990311. Miltgen J, Morillon M, Koeck J, Varnerot A, Briant J, Nguyen G, et al. Two Cases of Pulmonary Tuberculosis Caused by Mycobacterium tuberculosis subsp. canetti. Emerg Infect Dis. 2002;8(11):1350-1352. https://doi.org/10.3201/eid0811.020017. Huang SS, Labus BJ, Samuel MC, Wan DT, Reingold AL. Antibiotic Resistance Patterns of Bacterial Isolates from Blood in San Francisco County, California, 1996-1999. Emerg Infect Dis. 2002;8(2):195-201. https://doi.org/10.3201/eid0802.010102. Andraševiæ AT, Tambiæ T, Kaleniæ S, Jankoviæ V. Surveillance for Antimicrobial Resistance in Croatia. Emerg Infect Dis. 2002;8(1):14-18. https://doi.org/10.3201/eid0801.010143. Brown T, Nikolayevskyy V, Velji P, Drobniewski F. Associations between Mycobacterium tuberculosis Strains and Phenotypes. Emerg Infect Dis. 2010;16(2):272-280. https://doi.org/10.3201/eid1602.091032. Kirschner DE, Webb G. Resistance, Remission, and Qualitative Differences in HIV Chemotherapy. Emerg Infect Dis. 1997;3(3):273-283. https://doi.org/10.3201/eid0303.970303. Ijaz K, Yang Z, Matthews HS, Bates JH, Cave MD. Mycobacterium tuberculosis Transmission between Cluster Members with Similar Fingerprint Patterns. Emerg Infect Dis. 2002;8(11):1257-1259. https://doi.org/10.3201/eid0811.020284. Story A, Bothamley G, Hayward A. Crack Cocaine and Infectious Tuberculosis. Emerg Infect Dis. 2008;14(9):1466-1469. https://doi.org/10.3201/eid1409.070654. Mandalakas AM, Kay AW, Bacha JM, Devezin T, Golin R, Simon KR, et al. Tuberculosis among Children and Adolescents at HIV Treatment Centers in Sub-Saharan Africa. Emerg Infect Dis. 2020;26(12). https://doi.org/10.3201/eid2612.202245. Harbarth S, Albrich W, Brun-Buisson C. Outpatient Antibiotic Use and Prevalence of Antibiotic-Resistant Pneumococci in France and Germany: A Sociocultural Perspective. Emerg Infect Dis. 2002;8(12):1460-1467. https://doi.org/10.3201/eid0812.010533.

Download Document

Here is the link to download the presentation.
"Figure 2 Figure 2. Determination of prevalence of tuberculosis (TB) and drug"The content belongs to its owner. You may download and print it for personal use, without modification, and keep all copyright notices. By downloading, you agree to these terms.

Figure Figure. Kinetics of viremia, CD4+ T-cell count, and drug resistance mutations

Figure 4 Figure 4. Control measures for bovine tuberculosis based on test-and-slaughter

PPT-Figure 2 Figure 2. Determination of prevalence of tuberculosis (TB) and drug

Presentation Embed Code

Download Presentation

Figure 2 Figure 2. Determination of prevalence of tuberculosis (TB) and drug: Transcript

Figure Figure. Kinetics of viremia, CD4+ T-cell count, and drug resistance mutations

Figure 4 Figure 4. Control measures for bovine tuberculosis based on test-and-slaughter

Figure 1 Figure 1. Global incidence of tuberculosis. Of the estimated 8.8 million

Figure 1 Figure 1. Distribution of tuberculosis cases reported to health authorities

Figure 1 Figure 1. Colony morphology on Löwenstein-Jensen slants, showing M.

Figure 4 Figure 4. Yearly percent resistance to ciprofloxacin, ceftazidime, imipenem,

Figure 3 Figure 3. Resistance rates (%) to selected antimicrobial agents in gram-negative

Figure 1 Figure 1. Mycobacterium tuberculosis complex lineages as determined

Figure 5 Figure 5. 5a simulates combined drug treatment data reported for a patient

Figure 2 Figure 2. Epidemologic links among tuberculosis patients, Arkansas,

Figure Figure. Chest radiograph of a tuberculosis patient addicted to crack cocaine.

Figure 3 Figure 3. ART use and TB prevalence in HIV-infected children and adolescents,

Figure 1 Figure 1. Summary of published aggregate data on the prevalence of pneumococci

PPT-Figure 2 Figure 2.&nbsp;Determination of prevalence of tuberculosis (TB) and drug

Presentation Embed Code

Download Presentation

Figure 2 Figure 2.&nbsp;Determination of prevalence of tuberculosis (TB) and drug: Transcript

Figure Figure.&nbsp;Kinetics of viremia, CD4+ T-cell count, and drug resistance mutations

Figure 4 Figure 4.&nbsp;Control measures for bovine tuberculosis based on test-and-slaughter

Figure 1 Figure 1.&nbsp;Global incidence of tuberculosis. Of the estimated 8.8 million

Figure 1 Figure 1.&nbsp;Distribution of tuberculosis cases reported to health authorities

Figure 1 Figure 1.&nbsp;Colony morphology on Löwenstein-Jensen slants, showing M.

Figure 4 Figure 4.&nbsp;Yearly percent resistance to ciprofloxacin, ceftazidime, imipenem,

Figure 3 Figure 3.&nbsp;Resistance rates (%) to selected antimicrobial agents in gram-negative

Figure 1 Figure 1.&nbsp;Mycobacterium tuberculosis complex lineages as determined

Figure 5 Figure 5.&nbsp;5a simulates combined drug treatment data reported for a patient

Figure 2 Figure 2.&nbsp;Epidemologic links among tuberculosis patients, Arkansas,

Figure Figure.&nbsp;Chest radiograph of a tuberculosis patient addicted to crack cocaine.

Figure 3 Figure 3. ART use and TB prevalence in HIV-infected children and adolescents,

Figure 1 Figure 1.&nbsp;Summary of published aggregate data on the prevalence of pneumococci

PPT-Figure 2 Figure 2. Determination of prevalence of tuberculosis (TB) and drug

Figure 2 Figure 2. Determination of prevalence of tuberculosis (TB) and drug: Transcript

Figure Figure. Kinetics of viremia, CD4+ T-cell count, and drug resistance mutations

Figure 4 Figure 4. Control measures for bovine tuberculosis based on test-and-slaughter

Figure 1 Figure 1. Global incidence of tuberculosis. Of the estimated 8.8 million

Figure 1 Figure 1. Distribution of tuberculosis cases reported to health authorities

Figure 1 Figure 1. Colony morphology on Löwenstein-Jensen slants, showing M.

Figure 4 Figure 4. Yearly percent resistance to ciprofloxacin, ceftazidime, imipenem,

Figure 3 Figure 3. Resistance rates (%) to selected antimicrobial agents in gram-negative

Figure 1 Figure 1. Mycobacterium tuberculosis complex lineages as determined

Figure 5 Figure 5. 5a simulates combined drug treatment data reported for a patient

Figure 2 Figure 2. Epidemologic links among tuberculosis patients, Arkansas,

Figure Figure. Chest radiograph of a tuberculosis patient addicted to crack cocaine.

Figure 1 Figure 1. Summary of published aggregate data on the prevalence of pneumococci